საკვანძო სიტყვები
Movement Disorders
Schizophrenia
როგორ უნდა ციტირება
ანოტაცია
Background: Extrapyramidal symptoms (EPS) are prevalent side effects of antipsychotic medications in patients with schizophrenia. Identifying the demographic and clinical factors associated with EPS is essential for optimizing treatment strategies, and patient outcomes. Methods: A retrospective chart review was conducted among patients with schizophrenia receiving antipsychotic medications, focusing on EPS distributed into Parkinsonism, Acute Dystonia, Akathisia, and Tardive Dyskinesia. A total of 115 records were included in the analysis. Baseline disparities were evaluated using appropriate statistical tests. Factor Analysis, ANOVA, and partial correlation network analysis were employed to find out key contributors to EPS in schizophrenia patients. A multinomial logistic regression analysis was employed to examine the association of age, gender, and built type.
Results: The prevalence of extrapyramidal symptoms (EPS) was 38.3 percent, with Parkinsonism being most common (30.8%), followed by Tardive Dyskinesia (4.3%), Acute Dystonia (2.6%), and Akathisia (1.7%). EPS were more frequent in females, especially Parkinsonism and Tardive Dyskinesia. First-generation antipsychotics showed a higher EPS prevalence (66 %) compared to second-generation antipsychotics (34%). Significant differences in treatment duration and chlorpromazine equivalent dose were observed between EPS and non-EPS groups (p < 0.05). ANOVA showed a significant effect of symptom type on age (p = 0.014). Factor analysis (KMO 0.565, Bartlett p < 0.001) identified prescription pattern and body type as major contributors. Partial correlation analysis showed positive associations between body mass index, chlorpromazine dose, and treatment duration. Logistic regression revealed significant associations of Tardive Dyskinesia with age, Akathisia with athletic and pyknic body types (p < 0.001), and Dystonia with male gender and both body types (p < 0.001).
Conclusion: Female gender, asthenic body type, longer treatment duration, and higher chlorpromazine equivalent daily dose were significant predictors of EPS. Lower BMI was associated with Parkinsonism, suggesting a role of metabolic factors. EPS also correlated with increased healthcare utilization.
წყაროები
Rybakowski JK. Application of Antipsychotic Drugs in Mood Disorders. Brain Sciences. 2023;13:414.
Abu-Naser D, Gharaibeh S, Al Meslamani AZ, Alefan Q, Abunaser R. Assessment of Extrapyramidal Symptoms Associated with Psychotropics Pharmacological Treatments, and Associated Risk Factors. CPEMH. 2021;17:1–7.
Musco S, Ruekert L, Myers J, Anderson D, Welling M, Cunningham EA. Characteristics of Patients Experiencing Extrapyramidal Symptoms or Other Movement Disorders Related to Dopamine Receptor Blocking Agent Therapy. J Clin Psychopharmacol. 2019;39:336–43.
Abu-Naser D, Gharaibeh S, Al Meslamani AZ, Alefan Q, Abunaser R. Assessment of Extrapyramidal Symptoms Associated with Psychotropics Pharmacological Treatments, and Associated Risk Factors. CPEMH. 2021;17:1–7.
Pringsheim T, Doja A, Belanger S, Patten S, Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in Children (CAMESA) guideline group. Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth. Paediatr Child Health. 2011;16:590–8.
Services H, Abou-setta AM, Mousavi SS, Spooner C, Schouten JR, Pasichnyk D, et al. First-Generation Versus Second-Generation Antipsychotics in Adults : Comparative Effectiveness. 2012;
Makary S, Abd El Moez K, Elsayed M, Hassan H. Second-generation antipsychotic medications and metabolic disturbance in children and adolescents. Egypt J Neurol Psychiatry Neurosurg. 2023;59:14.
Kamaradova D, Latalova K, Prasko J, Kubinek R, Vrbova K, Mainerova B, et al. Connection between self-stigma, adherence to treatment, and discontinuation of medication. Patient Prefer Adherence. 2016;10:1289–98.
Mathews M, Gratz S, Adetunji B, George V, Mathews M, Basil B. Antipsychotic-induced movement disorders: evaluation and treatment. Psychiatry (Edgmont). 2005;2:36–41.
Høiberg MP, Nielsen B. Antipsychotic treatment and extrapyramidal symptoms amongst schizophrenic inpatients. Nordic Journal of Psychiatry. 2006;60:207–12.
Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry. 2018;17:341–56.
Ali OM, Breik M, Aly T, Raslan ATNE-D, Gheith M. Enhancing Data Analysis and Automation: Integrating Python with Microsoft Excel for Non-Programmers. JSEA. 2024;17:530–40.
Epskamp S, Borsboom D, Fried EI. Estimating psychological networks and their accuracy: A tutorial paper. Behav Res. 2018;50:195–212.
Blair RC, Higgins JJ. A Comparison of the Power of Wilcoxon’s Rank-Sum Statistic to that of Student’s t Statistic Under Various Nonnormal Distributions. Journal of Educational Statistics. 1980;5:309–35.
Grande RAN, Berdida DJE, Madkhali NAA, Aljaber NYA, Albagawi BS, Llaguno MBB, et al. Psychometric validity of the Arabic versions of the Simulation Design Scale, Educational Practices Questionnaire, and the Students Satisfaction and Self-Confidence in Learning Scale among Saudi nursing students. Teaching and Learning in Nursing. 2022;17:210–9.
Bhattacharyya S, Bandyopadhyay G. Comparative analysis using multinomial logistic regression. 2014 2nd International Conference on Business and Information Management (ICBIM) [Internet]. Durgapur, India: IEEE; 2014 [cited 2025 Jul 12]. p. 119–24. Available from: http://ieeexplore.ieee.org/document/6970970/
Weiden PJ. EPS Profiles: The Atypical Antipsychotics: Are Not All the Same. Journal of Psychiatric Practice. 2007;13:13–24.
Roiter B, Pigato G, Antonini A. Prevalence of Extrapyramidal Symptoms in In-Patients With Severe Mental Illnesses: Focus on Parkinsonism. Front Neurol. 2020;11:593143.
Ward KM, Citrome L. Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia—Key Differences in Pathophysiology and Clinical Management. Neurol Ther. 2018;7:233–48.
Yang JL, Hodara E, Sriprasert I, Shoupe D, Stanczyk FZ. Estrogen deficiency in the menopause and the role of hormone therapy: integrating the findings of basic science research with clinical trials. Menopause. 2024;31:926–39.
Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. TCRM. 2017;Volume 13:757–77.
Sugawara N, Maruo K, Sugai T, Suzuki Y, Ozeki Y, Shimoda K, et al. Prevalence of underweight in patients with schizophrenia: A meta-analysis. Schizophrenia Research. 2018;195:67–73.
Alavijeh MS, Chishty M, Qaiser MZ, Palmer AM. Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery. Neurotherapeutics. 2005;2:554–71.
Kadakia A, Brady BL, Dembek C, Williams GR, Kent M, Kadakia A, et al. The incidence and economic burden of extrapyramidal symptoms in patients with schizophrenia treated with second generation antipsychotics in a Medicaid population with schizophrenia treated with second generation antipsychotics in a. Journal of Medical Economics. 2022;25:87–98.